№ files_lp_3_process_9_62567
File format: docx
Character count: 3210
File size: 126 KB
This document provides the master authorisation sheet for the NHS Pharmacy Contraception Service, detailing the PGDs and the responsibilities of pharmacists and pharmacy technicians working under these guidelines.
Year:
2025
Region / City:
England
Subject:
NHS Pharmacy Contraception Service
Document Type:
Master Patient Group Direction (PGD) Sheet
Organization / Institution:
NHS
Author:
N/A
Target Audience:
Registered pharmacists and pharmacy technicians
Period of validity:
29/10/2025 to 28/02/2029
Approval Date:
October 2025
Amendment Date:
N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Year:
2023
Region / City:
Scotland
Topic:
Emergency Contraception, Bridging Contraception, Hormonal Contraception
Document Type:
Guidance
Author:
Faculty of Sexual and Reproductive Healthcare
Target Audience:
Community pharmacists, healthcare professionals
Period of validity:
2023-2024
Approval Date:
March 2017, amended July 2023
Date of Changes:
July 2023
Institution:
NHS Scotland
Healthcare Service:
Emergency Contraception, Bridging Contraception
Sexual Health:
Contraception, Pregnancy prevention
Eligibility:
Patients registered with a GP in Scotland, NHS Pharmacy First Scotland users
Conditions:
UKMEC categories, BMI considerations
Guidance:
Clinical, procedural recommendations
Service Specification No.:
Lot 6
Service:
Provision of Oral Emergency Contraception Services
Authority Lead:
Bernie Brown, Public Health, Derby City Council
Organisation:
Derby City Council
Period:
1 April 2022 – 31 March 2027 (with optional 1+1 year extensions)
Supporting Documentation:
Appendix A Care Pathway; Appendix B Patient Record – hard copy; Appendix C Patient Group Direction (PGD)
Geographical Area:
Derby City
Target Group:
Young women under 25 years of age
Clinical Focus:
Oral Emergency Contraception (Levonorgestrel), Ulipristal Acetate, Cu-IUD, Sexual Health, STI Prevention
Service Setting:
Primary Care
Related Services:
Integrated Sexual Health Service (ISHS); Derbyshire Community Health Services (DCHS)
Policy Framework:
Framework for Sexual Health Improvement in England; Public Health Outcomes Framework
Year:
2023
Country:
Scotland
Region:
Scotland
Subject:
Emergency contraception and bridging contraception
Document type:
Professional guidance
Issuing body:
NHS Scotland
Associated organization:
NHS 24
Note:
Associated organization
Faculty of Sexual and Reproductive Healthcare
Target audience:
Community pharmacists
Medicines referenced:
Ulipristal 30mg (EllaOne®), levonorgestrel, desogestrel
Legal framework:
Patient Group Directions (PGDs)
Geographical applicability:
Scotland
Amendment date:
July 2023
Year:
2025
Region / City:
England
Topic:
Emergency contraception
Document type:
Patient Group Direction (PGD)
Organization / Institution:
NHS England
Author:
Dr Cindy Farmer, Michelle Jenkins, Vicky Garner, Gail Rowley, Julia Hogan, Kate Devonport, Chetna Parmar, Helen Donovan, Carmel Lloyd, Clare Livingstone, Kirsty Armstrong, Dipti Patel, Emma Anderson, Dr Kathy French, Dr Sarah Pillai, Alison Crompton, Andrea Smith, Lisa Knight, Bola Sotubo, Tracy Rogers, Sandra Wolper, Jo Jenkins
Target audience:
Pharmacists, Pharmacy Technicians
Effective period:
June 2025 - February 2026
Approval date:
November 2022
Review date:
September 2025
Expiry date:
February 28, 2026
Year:
2025
Region / city:
United States
Topic:
Emergency Contraception
Document Type:
Clinical Practice Standard
Agency / Organization:
(insert AGENCY name)
Author:
(insert AGENCY name)
Target Audience:
Healthcare providers (MDs, NPs, PAs, DOs, NDs, RNs)
Effective Date:
January 2019
Revised Date:
January 2021, October 2022, January 2025
References:
U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC), U.S. Selected Practice Recommendations for Contraceptive Use (U.S. SPR), Contraceptive Technology, 21st Ed
Date of Approval:
Not specified
Date of Changes:
October 2022, January 2025
Year:
2025
Region / City:
England
Topic:
Emergency contraception, NHS Pharmacy Contraception Service
Document Type:
Patient Group Direction
Organization / Institution:
NHS England
Author:
Dr Cindy Farmer, Michelle Jenkins, Vicky Garner, Gail Rowley, Julia Hogan, Kate Devonport, Chetna Parmar, Helen Donovan, Carmel Lloyd, Clare Livingstone, Kirsty Armstrong, Dipti Patel, Emma Anderson, Dr Kathy French, Dr Sarah Pillai, Alison Crompton, Andrea Smith, Lisa Knight, Bola Sotubo, Tracy Rogers, Sandra Wolper, Jo Jenkins
Target Audience:
Community Pharmacists, Pharmacy Technicians
Effective Date:
29 October 2025
Review Date:
September 2028
Expiry Date:
28 February 2029
Approval Date:
November 2022
Document Status:
Draft
Document Version:
1.0
Change History:
Version 1.0 approved on 20 June 2025
Clinical Condition:
Unprotected sexual intercourse, contraceptive failure
Criteria for Inclusion:
Emergency contraception within 96 hours post-UPS, vomiting after EC
Criteria for Exclusion:
Age under 16, pregnancy, recent childbirth or miscarriage
Cautions:
Fraser guidelines for underage assessments, safeguarding protocols
Context:
A PGD outlining the conditions and procedures for emergency contraception administration by authorized pharmacists and technicians in NHS pharmacies in England.
Type of document:
Survey questionnaire
Target population:
Fathers of a new baby
Subject:
Zika virus, pregnancy, mosquito prevention, contraception, paternal involvement
Geographic reference:
Puerto Rico
Administering authority:
CDC/ATSDR Information Collection Review Office
Related program:
PRAMS (Pregnancy Risk Assessment Monitoring System)
Estimated completion time:
15 minutes
Data collection context:
Hospital-based survey
Regulatory reference:
OMB control number requirement
Topics covered:
Zika virus awareness, sexual transmission, microcephaly, mosquito bite prevention, condom use, contraception decision-making, prenatal care participation, employment information
Note:
Year
Theme:
Emergency Hormonal Contraception
Document Type:
Standard Operating Procedure (SOP)
Organization / Institution:
Pharmacy
Target Audience:
Pharmacists, Healthcare Professionals
Guidance:
The Pharmacy First Service for Emergency Hormonal Contraception (EHC)
Purpose:
To describe the process for implementing the Pharmacy First Service for Emergency Hormonal Contraception
Scope:
Provision of Emergency Hormonal Contraception to patients aged 13 and over by registered pharmacists
Year:
2003
Region / city:
Maine
Topic:
Emergency Contraception
Document type:
Statutory Law
Agency / Institution:
State of Maine
Author:
State of Maine
Target audience:
Publishers, Legal professionals
Validity period:
Until October 1, 2025
Approval date:
2003
Amendment date:
October 1, 2025
Legal disclaimer:
Required for republication
Context:
Legal text governing the publication and copyright of statutory materials from the State of Maine, with a focus on emergency contraception practice regulations.
Year:
2026
Region / City:
Israel
Topic:
Halacha, Contraception, Jewish Law
Document Type:
Shiur / Lecture Text
Institution:
Yeshivat Har Etzion, Koschitzky Virtual Beit Midrash
Author:
Laurie Novick
Editors:
Rav Ezra Bick, Ilana Elzufon, Shayna Goldberg
Audience:
Adult learners, students of Halacha
Period Covered:
Biblical times to modern contraceptive methods
Date Published:
2026
References:
Bereishit 38:7-10, Yevamot 34b, Nidda 13a, Tosafot Sanhedrin 59b, Tosafot Yevamot 12b, Rosh Ketubot 39a, Masechet Kalla Rabbati 2:7
Legal Focus:
Prohibition of hotza’at zera le-vatala, Hashchatat Zera, permissibility of contraceptive methods according to Halacha
Year:
2023
Region / City:
Lancashire
Theme:
Emergency Hormonal Contraception, Sexual Health
Document Type:
Service Specification
Organization:
Lancashire County Council
Author:
Marie Demaine
Target Audience:
Community Pharmacists, Health Care Professionals, Service Users
Period of Validity:
1st April 2023 – 31st March 2024
Approval Date:
2023-03-31
Modification Date:
N/A
Year:
2026
Region / City:
Chandigarh, India
Subject:
Vaginal contraception, microbiology
Document Type:
Research article
Institution:
Panjab University, Department of Microbiology
Author:
Siftjit Kaur, Vijay Prabha
Target Audience:
Researchers, healthcare professionals
Experimental Model:
Female BALB/c mice
Methodology:
Isolation, characterization, and in-vitro/in-vivo testing of sperm-agglutinating factor (SAF)
Safety Evaluation:
Vaginal epithelium integrity, reproductive performance, systemic toxicity
Number of Published Articles by Author:
111
Contact Email:
[email protected]
Alternative Email:
[email protected]
Phone Number:
+91 9417065675
Year:
2026
Region / city:
United Kingdom / New Zealand
Topic:
Contraception
Document type:
Standing Order
Institution:
Medical Centre or Clinic
Author:
Issuer of standing order
Target audience:
Women over 18 in UK MEC category one
Effective period:
One year from issue date
Issue date:
2026
Review date:
2027
Medication:
Levonorgestrel 150 mcg + ethinylestradiol 30 mcg tablet (Ava 30)
Route of administration:
Oral
Dosage:
One tablet daily
Quantity:
3 months initially, 6 months for continuation
Contraindications:
Patients outside UK MEC category one
Follow-up:
Monitor for contraindications, check BP and weight, verify understanding of the 7-day rule, assess compliance and STD/cervical screening needs
Training requirements:
Registered nurses must be trained and signed off as competent
Supporting documentation:
Healthpathways, Best Practice Journal, UK Medical Eligibility Criteria 2009, New Zealand Formulary, Standing Order Guidelines 2012, Medicines (Standing Order) Regulations 2012
Year:
2025
Region / city:
England
Topic:
Immunization
Document type:
Patient Group Direction (PGD)
Organization / institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Professor Shamez Ladhani, David Green
Target audience:
Healthcare professionals involved in immunization
Period of validity:
From 5 January 2026 to 5 January 2029
Approval date:
5 January 2026
Amendment date:
2 June 2025, 16 December 2025
Description:
A document detailing the administration guidelines for the pneumococcal polysaccharide conjugate vaccine (PCV13, PCV15) for children under 2 years old in the UK.
Year:
2025
Region / city:
England
Topic:
Influenza immunisation
Document type:
Patient Group Direction (PGD)
Organisation:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Jamie Lopez-Bernal, Greta Hayward
Target audience:
Healthcare practitioners, NHS organisations
Period of validity:
From 1 September 2025 to 1 April 2026
Approval date:
3 July 2025
Revision history:
Updated annually, latest update 9 July 2025
Reference no:
HPV (GBMSM) PGD
Version no:
v5.0
Valid from:
1 September 2025
Review date:
1 April 2028
Expiry date:
1 September 2028
Author:
Suki Hunjunt, Sharif Ismail, David Green
Region / city:
England
Target audience:
Healthcare practitioners administering HPV vaccine to GBMSM
Type of document:
Patient Group Direction
Organisation:
UK Health Security Agency (UKHSA)
Date of approval:
17 July 2025
Date of modifications:
16 July 2025
Context:
A formal Patient Group Direction for the administration of HPV vaccine to GBMSM, detailing legal, clinical, and procedural requirements for healthcare practitioners in England.
Reference no:
Hib/MenC PGD
Version no:
v6.0
Valid from:
1 July 2025
Expiry date:
30 April 2026
Authorising organisations:
UK Health Security Agency (UKHSA)
Target audience:
Registered healthcare practitioners
Responsible body:
UKHSA
Note:
Amendment history
v1.0 and v2.0:
See previous versions of this PGD template for details (19 January 2016 to 23 April 2018)
v3.0:
PHE Hib/MenC PGD amended to: include vaccination of individuals for the prevention of secondary cases of meningococcal group C disease (24 April 2018)
v4.0:
PHE Hib/MenC PGD amended to: remove reference to individuals with an underlying medical condition (5 March 2020)
v5.0:
UKHSA Hib/MenC PGD amended to: include minor rewording of standard text, layout and formatting changes (4 May 2022)
v6.0:
UKHSA Hib/MenC PGD amended to: include minor rewording, updated references, and changes to the childhood immunisation schedule (2 June 2025)
Developed by:
Christina Wilson (Lead Pharmacist), Professor Shamez Ladhani (Paediatric Infectious Diseases Consultant), David Green (Nurse Consultant for Immunisation Programmes)
Peer-reviewed by:
UKHSA Immunisations PGD Expert Panel
Date approved:
2 June 2025
Year:
2025
Region:
England
Subject:
Hepatitis B vaccination for renal patients
Document Type:
Patient Group Direction (PGD)
Authorising Organisation:
UK Health Security Agency (UKHSA)
Target Audience:
Registered healthcare professionals
Period of Validity:
28 February 2025 - 28 February 2028
Approval Date:
28 February 2025
Amendment Date:
21 February 2025